Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain

被引:0
作者
Alonso Hernandez, Angel [1 ]
Moreso, Francesc [2 ]
Bayes, Beatriz [3 ]
Lauzurica, Ricardo [3 ]
Sanz-Guajardo, Damaso [4 ]
Gomez-Huertas, Ernesto [5 ]
Pereira, Porfirio [6 ]
Paul, Javier [7 ]
Crespo, Josep [8 ]
Amenabar, Juan J. [9 ]
Oliver, Juan [1 ]
Seron, Daniel [2 ]
机构
[1] Hosp Univ A Coruna, Nephrol Dept, La Coruna, Spain
[2] Hosp Univ Vall DHebron, Nephrol Dept, Barcelona, Spain
[3] Hosp Germans Trias I Pujol, Dept Nephrol, Barcelona, Spain
[4] Hosp Univ bPuerta Hierro, Nephrol Dept, Madrid, Spain
[5] Hosp Cent Asturias, Dept Nephrol, Oviedo, Spain
[6] Hosp Virgen RocIo, Nephrol Dept, Seville, Spain
[7] Hosp Miguel Servet, Dept Nephrol, Zaragoza, Spain
[8] Hosp Peset, Dept Nephrol, Valencia, Spain
[9] Hosp Cruces, Dept Nephrol, Baracaldo, Spain
来源
CLINICAL KIDNEY JOURNAL | 2010年 / 3卷
关键词
angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; graft survival; renal transplantation;
D O I
10.1093/ndtplus/sfq068
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (>= 18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17-0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort.
引用
收藏
页码:II21 / II25
页数:5
相关论文
共 17 条
  • [1] Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy
    Amara, Alieu B.
    Sharma, Asheesh
    Alexander, John L.
    Alfirevic, Ana
    Mohiuddin, Atif
    Pirmohamed, Munir
    Close, Graeme L.
    Grime, Steve
    Maltby, Paul
    Shawki, Howida
    Heyworth, Sally
    Shenkin, Alan
    Smith, Linda
    Sharma, Ajay K.
    Hammad, Abdel
    Rustom, Rana
    [J]. TRANSPLANTATION, 2010, 89 (01) : 104 - 114
  • [2] Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy
    Artz, MA
    Hilbrands, LB
    Borm, G
    Assmann, KJM
    Wetzels, JFM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (11) : 2852 - 2857
  • [3] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [4] Is There Added Value to Adding ARB to ACE Inhibitors in the Management of CKD?
    Cohen, Debbie L.
    Townsend, Raymond R.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (08): : 1666 - 1668
  • [5] Effect of angiotensin II receptor blocker on plasma levels of TGF-β1 and interstitial fibrosis in hypertensive kidney transplant patients
    El-Agroudy, AE
    Hassan, NA
    Foda, MA
    Ismail, AM
    El-Sawy, EA
    Mousa, O
    Ghoneim, MA
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (05) : 300 - 306
  • [6] Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation
    Heinze, Georg
    Mitterbauer, Christa
    Regele, Heinz
    Kramar, Reinhard
    Winkelmayer, Wolfgang C.
    Curhan, Gary C.
    Oberbauer, Rainer
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (03): : 889 - 899
  • [7] Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence
    Hiremath, S.
    Fergusson, D.
    Doucette, S.
    Mulay, A. V.
    Knoll, G. A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (10) : 2350 - 2360
  • [8] The burden of chronic kidney disease in renal transplant recipients
    Karthikeyan, V
    Karpinski, J
    Nair, RC
    Knoll, G
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) : 262 - 269
  • [9] THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY
    LEWIS, EJ
    HUNSICKER, LG
    BAIN, RP
    ROHDE, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) : 1456 - 1462
  • [10] Angiotensin converting enzyme inhibition in chronic allograft nephropathy
    Lin, J
    Valeri, AM
    Markowitz, GS
    D'Agati, VD
    Cohen, DJ
    Radhakrishnan, J
    [J]. TRANSPLANTATION, 2002, 73 (05) : 783 - 788